The buzz about a possible acquisition of Nektar Therapeutics $NKTR has been intense over the last few weeks, especially as new M&A deals have begun to pour through. So maybe it’s not a huge surprise to hear that Bloomberg is reporting Friday afternoon that the biotech is exploring its options, and perhaps a sale.
Nektar spotlighted NKTR-214 at SITC last fall, raising interest for a therapy that hopes to make waves in I/O.
The drug is an IL-2 immuno-oncology therapy — built from the ground up by the biotech — which is designed to bind to the CD122 receptor on the surface of CD-8 and CD-4 positive immune cells to whip up an attack on various cancers. Nektar struck a 50/50 deal with Bristol-Myers Squibb $BMY to use their drug in combination with Opdivo (nivolumab), matching a therapy aimed at driving an immune response with a popular checkpoint blockbuster that helps take the brakes off the assault.
There’s also a late-stage program underway for a pain drug called NKTR-181.
It hasn’t all been a bed of roses for Nektar over the past year. The biotech attempted to win an accelerated European OK for its cancer drug Onzeald (NKTR-102), but ran straight into a regulatory brick wall. The CHMP voted thumbs down on Onzeald, which was also bad news for Daiichi Sankyo, which bet $20 million upfront on a regional licensing pact for the drug. Daiichi recently signaled that it wanted to bail on the deal.
We’ve seen a string of biotech buyouts in the weeks following JP Morgan, as companies make adjustments to their plans based on the long awaited tax reform bill. And more are expected.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 25,000+ biopharma pros who read Endpoints News by email every day.Free Subscription